CN Patent

CN102895204B — 一种用于制备片剂的碳酸司维拉姆原料药及其制备方法和应用

Assigned to NANJING HENCER PHARMACY CO., LTD. · Expires 2014-12-31 · 11y expired

What this patent protects

本发明属于制药领域，涉及一种用于制备片剂的碳酸司维拉姆原料药及其制备方法和应用。该原料药其粒径同时满足以下条件：D0.95不大于180μm，D0.50不大于50μm，D0.05不小于9μm。在此粒度范围内的聚烯丙胺碳酸盐具有可溶性低聚物<0.2%。且用该原料药所制片剂的表面比较光滑，硬度好，脆碎度低的优点。

USPTO Abstract

本发明属于制药领域，涉及一种用于制备片剂的碳酸司维拉姆原料药及其制备方法和应用。该原料药其粒径同时满足以下条件：D0.95不大于180μm，D0.50不大于50μm，D0.05不小于9μm。在此粒度范围内的聚烯丙胺碳酸盐具有可溶性低聚物<0.2%。且用该原料药所制片剂的表面比较光滑，硬度好，脆碎度低的优点。

Drugs covered by this patent

Patent Metadata

Patent number
CN102895204B
Jurisdiction
CN
Classification
—
Expires
2014-12-31
Drug substance claim
No
Drug product claim
No
Assignee
NANJING HENCER PHARMACY CO., LTD.
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.